Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.

Nersting J, Nielsen SN, Grell K, Paerregaard M, Abrahamsson J, Lund B, Jonsson OG, Pruunsild K, Vaitkeviciene G, Kanerva J, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO).

Cancer Chemother Pharmacol. 2019 Jan;83(1):53-60. doi: 10.1007/s00280-018-3704-7. Epub 2018 Oct 15.

PMID:
30324220
2.

NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.

Tulstrup M, Grosjean M, Nielsen SN, Grell K, Wolthers BO, Wegener PS, Jonsson OG, Lund B, Harila-Saari A, Abrahamsson J, Vaitkeviciene G, Pruunsild K, Toft N, Holm M, Hulegårdh E, Liestøl S, Griskevicius L, Punab M, Wang J, Carroll WL, Zhang Z, Dalgaard MD, Gupta R, Nersting J, Schmiegelow K.

Leukemia. 2018 Dec;32(12):2527-2535. doi: 10.1038/s41375-018-0245-3. Epub 2018 Sep 10.

PMID:
30201983
3.

Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men With Inflammatory Bowel Disease.

Grosen A, Nersting J, Bungum M, Christensen LA, Schmiegelow K, Spanò M, Julsgaard M, Cordelli E, Leter G, Larsen PB, Hvas CL, Kelsen J.

J Crohns Colitis. 2019 Jan 1;13(1):3-11. doi: 10.1093/ecco-jcc/jjy086.

PMID:
29917107
4.

Testing physical function in children undergoing intense cancer treatment-a RESPECT feasibility study.

Nielsen MKF, Christensen JF, Frandsen TL, Thorsteinsson T, Andersen LB, Christensen KB, Nersting J, Faber M, Schmiegelow K, Larsen HB.

Pediatr Blood Cancer. 2018 Aug;65(8):e27100. doi: 10.1002/pbc.27100. Epub 2018 May 9.

PMID:
29741279
5.

Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.

Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.

Dig Dis Sci. 2018 Jun;63(6):1583-1591. doi: 10.1007/s10620-018-5020-9. Epub 2018 Mar 21.

PMID:
29564674
6.

MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.

Evensen NA, Madhusoodhan PP, Meyer J, Saliba J, Chowdhury A, Araten DJ, Nersting J, Bhatla T, Vincent TL, Teachey D, Hunger SP, Yang J, Schmiegelow K, Carroll WL.

Haematologica. 2018 May;103(5):830-839. doi: 10.3324/haematol.2017.176362. Epub 2018 Feb 15.

7.

Role of TPMT and ITPA variants in mercaptopurine disposition.

Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K.

Cancer Chemother Pharmacol. 2018 Mar;81(3):579-586. doi: 10.1007/s00280-018-3525-8. Epub 2018 Feb 1.

PMID:
29387964
8.

A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.

Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.

J Crohns Colitis. 2018 Feb 28;12(3):298-305. doi: 10.1093/ecco-jcc/jjx149.

PMID:
29145599
9.

Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.

Toksvang LN, De Pietri S, Nielsen SN, Nersting J, Albertsen BK, Wehner PS, Rosthøj S, Lähteenmäki PM, Nilsson D, Nystad TA, Grell K, Frandsen TL, Schmiegelow K.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26519. Epub 2017 Apr 19. Erratum in: Pediatr Blood Cancer. 2018 Jan;65(1):.

PMID:
28423235
10.

DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.

Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K.

Lancet Oncol. 2017 Apr;18(4):515-524. doi: 10.1016/S1470-2045(17)30154-7. Epub 2017 Mar 1.

PMID:
28258828
11.

Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia.

Ebbesen MS, Nygaard U, Rosthøj S, Sørensen D, Nersting J, Vettenranta K, Wesenberg F, Kristinsson J, Harila-Saari A, Schmiegelow K.

J Pediatr Hematol Oncol. 2017 Apr;39(3):161-166. doi: 10.1097/MPH.0000000000000733.

PMID:
28060115
12.

Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.

Nielsen SN, Grell K, Nersting J, Frandsen TL, Hjalgrim LL, Schmiegelow K.

Cancer Chemother Pharmacol. 2016 Nov;78(5):983-994. Epub 2016 Sep 6.

PMID:
27600880
13.

Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?

Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, Vettenranta K, Schrøeder H, Weinshilboum R, Jensen KL, Grell K, Rosthoej S.

Pediatr Blood Cancer. 2016 Dec;63(12):2104-2111. doi: 10.1002/pbc.26139. Epub 2016 Jul 22.

PMID:
27447547
14.

NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.

Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, Hofmann U, Komada Y, Kato M, McCorkle R, Li L, Koh K, Najera CR, Kham SK, Isobe T, Chen Z, Chiew EK, Bhojwani D, Jeffries C, Lu Y, Schwab M, Inaba H, Pui CH, Relling MV, Manabe A, Hori H, Schmiegelow K, Yeoh AE, Evans WE, Yang JJ.

Nat Genet. 2016 Apr;48(4):367-73. doi: 10.1038/ng.3508. Epub 2016 Feb 15.

15.

Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children.

Tiphaine Ade B, Hjalgrim LL, Nersting J, Breitkreutz J, Nelken B, Schrappe M, Stanulla M, Thomas C, Bertrand Y, Leverger G, Baruchel A, Schmiegelow K, Jacqz-Aigrain E.

Eur J Pharm Sci. 2016 Feb 15;83:1-7. doi: 10.1016/j.ejps.2015.12.002. Epub 2015 Dec 2.

PMID:
26657824
16.

Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.

Vang SI, Schmiegelow K, Frandsen T, Rosthøj S, Nersting J.

Cancer Chemother Pharmacol. 2015 May;75(5):1089-93. doi: 10.1007/s00280-015-2717-8. Epub 2015 Mar 19.

PMID:
25788208
17.

Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.

Nielsen SN, Frandsen TL, Nersting J, Hjalgrim LL, Schmiegelow K.

J Pediatr Hematol Oncol. 2015 Apr;37(3):e206-9. doi: 10.1097/MPH.0000000000000246.

PMID:
25171455
18.

Treatment-related myelodysplastic syndrome in a child with acute myeloid leukemia and TPMT heterozygosity.

Stensman LM, Kjeldsen E, Nersting J, Schmiegelow K, Hasle H.

J Pediatr Hematol Oncol. 2015 May;37(4):e242-4. doi: 10.1097/MPH.0000000000000211.

PMID:
25000470
19.

Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J.

J Pediatr Hematol Oncol. 2014 Oct;36(7):503-17. doi: 10.1097/MPH.0000000000000206. Review.

20.

Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.

Henriksen LT, Nersting J, Raja RA, Frandsen TL, Rosthøj S, Schrøder H, Albertsen BK; Nordic Society of Paediatric Haematology and Oncology (NOPHO) group.

Br J Haematol. 2014 Jul;166(2):213-20. doi: 10.1111/bjh.12865. Epub 2014 Apr 5.

PMID:
24702187
21.

Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.

Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology, Oncology.

Pediatr Blood Cancer. 2014 May;61(5):797-802. doi: 10.1002/pbc.24921. Epub 2014 Jan 3.

PMID:
24395436
22.

Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed MTX excretion after high dose of methotrexate?

Rasmussen MM, Christensen RH, Gregers J, Heldrup J, Nersting J, Schmiegelow K.

J Pediatr Hematol Oncol. 2013 Jul;35(5):417-8. doi: 10.1097/MPH.0b013e318290c11c. No abstract available.

PMID:
23669721
23.

Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes.

Ebbesen MS, Nersting J, Jacobsen JH, Frandsen TL, Vettenranta K, Abramsson J, Wesenberg F, Schmiegelow K.

J Clin Pharmacol. 2013 Jun;53(6):670-4. doi: 10.1002/jcph.81. Epub 2013 Apr 15. No abstract available.

PMID:
23585236
24.

Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard.

Jacobsen JH, Schmiegelow K, Nersting J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jan 15;881-882:115-8. doi: 10.1016/j.jchromb.2011.11.032. Epub 2011 Nov 28.

PMID:
22178190
25.

Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.

Nersting J, Borst L, Schmiegelow K.

Clin Proteomics. 2011 Jun 3;8(1):8. doi: 10.1186/1559-0275-8-8.

26.

Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia.

Wesolowska A, Dalgaard MD, Borst L, Gautier L, Bak M, Weinhold N, Nielsen BF, Helt LR, Audouze K, Nersting J, Tommerup N, Brunak S, Sicheritz-Ponten T, Leffers H, Schmiegelow K, Gupta R.

Leukemia. 2011 Jun;25(6):1001-6. doi: 10.1038/leu.2011.32. Epub 2011 Mar 18.

PMID:
21415851
27.

Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates.

Lausten-Thomsen U, Madsen HO, Vestergaard TR, Hjalgrim H, Nersting J, Schmiegelow K.

Blood. 2011 Jan 6;117(1):186-9. doi: 10.1182/blood-2010-05-282764. Epub 2010 Aug 16.

28.

Pharmacogenomics of methotrexate: moving towards individualized therapy.

Nersting J, Schmiegelow K.

Pharmacogenomics. 2009 Dec;10(12):1887-9. doi: 10.2217/pgs.09.148. No abstract available.

29.

DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.

Hedeland RL, Hvidt K, Nersting J, Rosthøj S, Dalhoff K, Lausen B, Schmiegelow K.

Cancer Chemother Pharmacol. 2010 Aug;66(3):485-91. doi: 10.1007/s00280-009-1184-5. Epub 2009 Dec 3.

PMID:
19956952
30.

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology.

Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17.

31.

Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression.

Mikkelsen M, Sønder SU, Nersting J, Bendtzen K.

Apoptosis. 2006 Apr;11(4):573-9.

PMID:
16528473
32.
33.

[Autoinflammatory disease: a new concept].

Nersting J, Andersen V, Bendtzen K.

Ugeskr Laeger. 2002 Sep 9;164(37):4269-71. Danish. No abstract available.

PMID:
12362866

Supplemental Content

Loading ...
Support Center